» Articles » PMID: 34610896

Should Non-invasive Diffuse Main-duct Intraductal Papillary Mucinous Neoplasms Be Treated with Total Pancreatectomy?

Overview
Journal HPB (Oxford)
Publisher Elsevier
Specialty Gastroenterology
Date 2021 Oct 6
PMID 34610896
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Main-duct (MD) intraductal papillary mucinous neoplasm (IPMN) is associated with malignancy risk. There is a lack of consensus on treatment (partial or total pancreatectomy) when the MD is diffusely involved. We sought to characterize the pancreatic remnant fate after partial pancreatectomy for non-invasive diffuse MD-IPMN.

Methods: Consecutive patients with partial pancreatectomy for non-invasive MD-IPMN from 2004 to 2016 were analyzed. Diffuse MD-IPMN was defined by preoperative imaging as dilation of the MD in the head of the pancreas more than 5 mm and involving the whole gland.

Results: Of 127 patients with resected non-invasive MD-IPMN, 47 (37%) had diffuse MD involvement. Eleven of 47(23%) patients developed imaging evidence of progression or new cystic disease in the pancreatic remnant. Patients with diffuse MD-IPMN were older (73yrs vs 67yrs, p = 0.009), more likely to receive a pancreaticoduodenectomy (96% vs 56%, p < 0.001) and have high-grade dysplasia (51% vs 31%, p = 0.025) than those with focal MD involvement. Diffuse MD involvement was not associated with shorter PFS following partial pancreatectomy (p = 0.613).

Conclusion: Partial pancreatectomy is an appropriate surgical approach for diffuse MD-IPMN, and is not associated with earlier progression after surgery as compared to partial pancreatectomy for focal dilation.

Citing Articles

Recurrence following Resection of Intraductal Papillary Mucinous Neoplasms: A Systematic Review to Guide Surveillance.

Salahuddin A, Thayaparan V, Hamad A, Tarver W, Cloyd J, Kim A J Clin Med. 2024; 13(3).

PMID: 38337524 PMC: 10856514. DOI: 10.3390/jcm13030830.

References
1.
Fritz S, Schirren M, Klauss M, Bergmann F, Hackert T, Hartwig W . Clinicopathologic characteristics of patients with resected multifocal intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2012; 152(3 Suppl 1):S74-80. DOI: 10.1016/j.surg.2012.05.025. View

2.
Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang J, Levy P, Ohtsuka T . Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17(5):738-753. DOI: 10.1016/j.pan.2017.07.007. View

3.
Bassi C, Crippa S, Salvia R . Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife?. Gut. 2008; 57(3):287-9. DOI: 10.1136/gut.2007.135392. View

4.
Simpson R, Ceppa E, Wu H, Akisik F, House M, Zyromski N . The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. J Gastrointest Surg. 2019; 23(8):1593-1603. DOI: 10.1007/s11605-018-4026-0. View

5.
Borgo C, Perri G, Borin A, Marchegiani G, Salvia R, Bassi C . The Clinical Management of Main Duct Intraductal Papillary Mucinous Neoplasm of the Pancreas. Dig Surg. 2018; 36(2):104-110. DOI: 10.1159/000486869. View